Cardiovascular Agents

• 

  Subject Areas on Research

  • "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. 
  • 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. 
  • 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
  • 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. 
  • 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • A health literacy pilot intervention to improve medication adherence using Meducation® technology. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Adenosine for myocardial protection in acute myocardial infarction. 
  • Adenosine-induced transient asystole for intracranial aneurysm surgery: a retrospective review. 
  • Adherence to Guideline-Recommended Therapy-Including Supervised Exercise Therapy Referral-Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. 
  • Adverse drug events in high risk older outpatients. 
  • Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time. 
  • American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. 
  • Antianginal therapy before percutaneous coronary intervention. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. 
  • BNP-guided heart failure therapy in older patients. 
  • BNP-guided therapy for heart failure. 
  • Back to the future: improving the use of guidelines-recommended coronary disease secondary prevention at the dawn of the precision medicine era. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. 
  • Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications. 
  • Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. 
  • Calcineurin signaling in human cardiac hypertrophy. 
  • Cardiac allograft vasculopathy: A review. 
  • Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. 
  • Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications. 
  • Cardiovascular Drug Pricing: Less Innovation for More Access? 
  • Cardiovascular Medications and Fractures: Dodging Complexity. 
  • Cardiovascular drug development: is it dead or just hibernating? 
  • Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. 
  • Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). 
  • Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020. 
  • Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. 
  • Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study. 
  • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. 
  • Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. 
  • Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 
  • Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus. 
  • Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. 
  • Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. 
  • Complement activation and cardiac surgery: a novel target for improving outcomes. 
  • Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. 
  • Contemporary Applications of Machine Learning for Device Therapy in Heart Failure. 
  • Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. 
  • Contemporary therapy of acute ST-elevation myocardial infarction. 
  • Cost of ventricular assist devices: can we afford the progress? 
  • Criteria for dose-finding in two-stage seamless adaptive design. 
  • Cumulative Cardiovascular Polypharmacy Is Associated With the Risk of Acute Kidney Injury in Elderly Patients. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. 
  • Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. 
  • Decongestion in acute heart failure. 
  • Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies. 
  • Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience. 
  • Developing New Treatments for Heart Failure: Focus on the Heart. 
  • Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy: JACC Focus Seminar 4/5. 
  • Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction. 
  • Disease management of congestive heart failure. 
  • Does ranolazine have a place in the treatment of acute coronary syndromes? 
  • Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. 
  • Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? 
  • Drug-induced lung injury. 
  • Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). 
  • Economic end points in phase II trials. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis. 
  • Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. 
  • Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. 
  • Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris. 
  • Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. 
  • Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. 
  • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 
  • Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. 
  • Enabling social listening for cardiac safety monitoring: Proceedings from a drug information association-cardiac safety research consortium cosponsored think tank. 
  • Endpoints in Heart Failure Drug Development: History and Future. 
  • Enhancement of cardiac function by cyclocreatine in models of cardiopulmonary bypass. 
  • Enhancement of the force-frequency effect on myocardial contractility by adrenergic stimulation in conscious dogs. 
  • Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. 
  • Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. 
  • Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs. 
  • Evidence-based therapy prescription in high-cardiovascular risk patients: the REACT study. 
  • Extended-release ranolazine: critical evaluation of its use in stable angina. 
  • Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI. 
  • Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries. 
  • Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. 
  • Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. 
  • G-Protein-Coupled Receptors in Heart Disease. 
  • GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs. 
  • Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. 
  • Gender differences in the treatment of non-ST-segment elevation myocardial infarction. 
  • Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 
  • Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. 
  • Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals: Findings From Get With The Guidelines-Heart Failure. 
  • Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure. 
  • Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • High-resolution CT of drug-induced lung disease. 
  • Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. 
  • Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. 
  • ISCHEMIA: Establishing the Primary End Point. 
  • Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality. 
  • Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. 
  • Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. 
  • In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 
  • Indications for pacing in the treatment of bradyarrhythmias. Report of an independent study group. 
  • Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. 
  • Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 
  • International variation in the use of evidence-based medicines for acute coronary syndromes. 
  • Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Intramyocardial, autologous CD34+ cell therapy for refractory angina. 
  • Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. 
  • Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. 
  • Issues with care in the elderly patient presenting with acute ischemia. 
  • Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Lessons learned from clinical trials in acute heart failure: phase 3 drug trials. 
  • Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. 
  • Long-Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. 
  • Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. 
  • Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. 
  • Lower extremity amputation in peripheral artery disease: improving patient outcomes. 
  • Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 
  • Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. 
  • Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. 
  • Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery ® and the American Venous Forum. 
  • Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. 
  • Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Medical and surgical management of coronary artery disease in women. 
  • Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. 
  • Medication adherence: a call for action. 
  • Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. 
  • Medication non-adherence after myocardial infarction: an exploration of modifying factors. 
  • Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. 
  • Metaanalysis and review of heart failure disease management randomized controlled clinical trials. 
  • Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. 
  • Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. 
  • New precompetitive paradigms: focus on cardiac safety. 
  • Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. 
  • Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. 
  • Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. 
  • Outpatient management of heart failure in the United States, 2006-2008. 
  • PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories): Overview of Design and Rationale of an International Prospective Peripheral Arterial Disease Study. 
  • Paroxysmal high-grade atrioventricular block and syncope in a previously healthy child: what is the mechanism? 
  • Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. 
  • Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). 
  • Patient-Reported Outcome Measures in Cardiovascular Disease: An Evidence Map of the Psychometric Properties of Health Status Instruments. 
  • Patient-centered adherence intervention after acute coronary syndrome hospitalization. 
  • Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. 
  • Pediatric cardiovascular drug trials, lessons learned. 
  • Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry. 
  • Perioperative Quality Initiative consensus statement on preoperative blood pressure, risk and outcomes for elective surgery. 
  • Perioperative management of drug therapy, clinical considerations. 
  • Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. 
  • Personalized Therapeutic Approach: Gun Control for Shotgun Therapy. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pharmacogenetics in heart failure trials. 
  • Pharmacological and emerging therapies in the treatment of chronic angina. 
  • Pharmacological properties of tropyl benzilate hydrochloride (BAT) and its N-allyl derivative (NTB). 
  • Pharmacological therapy for myocardial reperfusion injury. 
  • Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop. 
  • Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. 
  • Pheochromocytoma complicated with cardiomyopathy after delivery--a case report and literature review. 
  • PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. 
  • Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population. 
  • Porphyrin-Based SOD Mimic MnTnBu OE -2-PyP5+ Inhibits Mechanisms of Aortic Valve Remodeling in Human and Murine Models of Aortic Valve Sclerosis. 
  • Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? 
  • Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. 
  • Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. 
  • PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. 
  • Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. 
  • Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. 
  • Provisional stenting versus routine stenting: is it worth the price? 
  • Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants. 
  • Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons: A Call to Action. 
  • Pulmonary drug toxicity: radiologic and pathologic manifestations. 
  • Putting the Acute Coronary Syndrome in Context After 80 Years of Age. 
  • Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). 
  • Quantifying the utility of taking pills for cardiovascular prevention. 
  • Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). 
  • Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. 
  • Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). 
  • Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. 
  • Rationale and Design of the VITALITY-HFpEF Trial. 
  • Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. 
  • Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. 
  • Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. 
  • Recurrence of local anesthetic cardiac toxicity or hypokalemia? 
  • Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. 
  • Renal function and coronary bypass surgery in patients with ischemic heart failure. 
  • Renal function, concomitant medication use and outcomes following acute coronary syndromes. 
  • Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. 
  • Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. 
  • Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients. 
  • SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention. 
  • Sample size and interim analysis issues for dose selection. 
  • Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Sex Differential in 15-Hydroxyprostaglandin Dehydrogenase Levels in the Lumen of Human Intracranial Aneurysms. 
  • Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. 
  • Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. 
  • Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. 
  • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. 
  • Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. 
  • Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 
  • Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. 
  • Surgical correction of aortic valve insufficiency after left ventricular assist device implantation. 
  • Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 
  • Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. 
  • Synergistic effects of exposure to concentrated ambient fine pollution particles and nitrogen dioxide in humans. 
  • Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot? 
  • Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. 
  • Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry. 
  • Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. 
  • The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. 
  • The Cardiac Safety Research Consortium enters its second decade: An invitation to participate. 
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. 
  • The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. 
  • The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. 
  • The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. 
  • The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study. 
  • The disconnect between phase II and phase III trials of drugs for heart failure. 
  • The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. 
  • The impact of medication use in a multicomponent intervention: results from the WISEWOMAN program. 
  • The meanings associated with medicines in heart failure patients. 
  • The neurohormonal network in the RAAS can bend before breaking. 
  • The process of bringing new drug-eluting stents to market will they see the light of day? 
  • The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. 
  • The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. 
  • The use of vasoactive agents via peripheral intravenous access during transport of critically III infants and children. 
  • Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. 
  • Therapy insight: how changes in renal function with increasing age affect cardiovascular drug prescribing. 
  • Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure. 
  • Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. 
  • Translating the Secondary Prevention Therapeutic Boom Into Action. 
  • Translation of acute coronary syndrome therapies: from evidence to routine clinical practice. 
  • Treatment of non-ST-elevation acute coronary syndrome in the elderly: current practice and future opportunities. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database. 
  • Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. 
  • Update on perioperative care of the cardiac patient for noncardiac surgery. 
  • Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. 
  • Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. 
  • Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. 
  • Use of guideline-recommended therapies for heart failure in the Medicare population. 
  • Using measures of disease progression to determine therapeutic effect: a sirens' song. 
  • What can heart failure trialists learn from oncology trialists? 
  • Whatever happened to the polypill? 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology